This website uses cookies to ensure you have the best user experience. By continuing to use this website, you consent to our use of cookies. For more information, read our privacy policy.
This is a test.
Studying the evolution of high-grade serous ovarian cancer after targeted therapy
This is a test.
Identifying biomarkers of immunotherapy response in ovarian clear cell carcinoma
This is a test.
Testing a novel HER2-targeted combination treatment for ovarian cancer
This is a test.
Anti-estrogen therapy and ER/PR expression in low-grade serous ovarian cancer
This is a test.
Testing a novel treatment target in clear cell ovarian cancer
This is a test.
NEOCATS trial: Targeting the targets with a combination of three treatments
This is a test.
ES2 trial: combining a PARP inhibitor and apoptosis sensitizer
This is a test.
Phase II clinical trial of CX5461 at the time of disease progression on a PARP inhibitor
This is a test.
Re-VOLVE trial: using genomics to make treatment decisions after a PARP inhibitor
This is a test.
Developing new treatments for clear cell ovarian cancer
